Results 71 to 80 of about 1,885,648 (256)

Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study [PDF]

, 2004
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C ...
Achiti, J., Arbizu, T., Arnulf, I., Aubertin, P., Bamborschke, P., Belliard, S., Berger, E., Blanc, S., Brassat, D., Brochet, B., Cahagne, V., Casado, A., Cesaro, P., Chan, A., Clanet, M., Confavreux, C., Dalecky, A., Damier, P., de Keyser, Jacques, de Marco, A., Defer, G., Degos, F., Dengler, R., Dose, A., Edan, G., Engles, A., Fernandez, O., Flachenecker, A., Gayou, A., Gelderblom, H., Grunwald, F., Grupe, A., Hartung, H.P., Heesen, C., Heidenreich, F., Heinzlef, O., Hohlfeld, R., Kappos, L., Kassim, N., Koehler, A., Koerner, A., Kristoferitsch, W., Kunze, K., Kyriallis, K., Lau, G., Lecanuet, P., Lindert, A., Liu, A., Lubetzki, C., Luenemann, J., Lyon-Caen, O., Magnier, C., Martin, A, Martinez-Yelamos, A., Matzke, A., Maurer, A., Mekies, C., Menck, A., Montalban, X., Moulin, A., Nolden, A., Nos, A., Pantzaris, A., Papacostas, S., Pelletier, J., Petereit, H., Pez, D., Piette, A., Riche, G., Rieckmann, P., Romero, F., Rouanet, M., Rouant, F., Roullet, E., Rumbach, L., Sailer, 27449, Schaeffer, S., Schlederer, A., Schrieber, A., Seeldrayers, P., Senard, A., Stankoff, B., Steiner, A., Stingle, A., Storch-Hagenlocher, A., Storch-Hagenlocher, B., Suchet, L., Tamayo, J.A., Tamman, D., Thalamas, C., Vermersch, P., Vogt-Schaden, A., Vuilleman, C., Weilbach, A., Weiler, C., Windhagen, A., Zorgdrager, A., Zschenderlein, R., Zwanniken, G.   +98 more
core   +1 more source

Adjunctive Therapeutic Plasma Exchange in Refractory Adult‐Onset Still's Disease Complicated by Secondary Macrophage Activation Syndrome: A Single‐Center Experience

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Adult‐onset Still's disease (AOSD) complicated by macrophage activation syndrome (MAS) carries substantial mortality. The role of therapeutic plasma exchange (TPE) remains uncertain. Methods We retrospectively analyzed patients with AOSD‐MAS treated with TPE at a single‐center.
Masataka Ueda, Tomohiro Saito, Masahide Mizobuchi, Tomoki Shimomura, Saki Kawamori, Mitsuru Kawanishi, Natsuko Hattori, Jo Sugiyama, Satoshi Tsubata, Hanami Horiguchi, Kazuki Abe, Nao Iida, Yuki Kajio, Nao Oguro, Ryo Yanai, Hirokazu Honda   +15 more
wiley   +1 more source

Bitter orange (Citrus aurantium L.) extract subchronic 90-day safety study in rats

Toxicology Reports, 2017
Bitter orange (Citrus aurantium L.) extracts are widely used in dietary supplements and bitter oranges are used in various juices and food products. p-Synephrine, the primary active constituent, comprises approximately 90% of total protoalkaloids.
N.S. Deshmukh, S.J. Stohs, C.C. Magar, A. Kale, B. Sowmya   +4 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

no observed adverse effect level

, 2014
Citation: 'no observed adverse effect level' in the IUPAC Compendium of Chemical Terminology, 3rd ed.; International Union of Pure and Applied Chemistry; 2006. Online version 3.0.1, 2019. 10.1351/goldbook.NT06911 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

Leveraging Epidemiology to Improve Risk Assessment. [PDF]

, 2011
The field of environmental public health is at an important crossroad. Our current biomonitoring efforts document widespread exposure to a host of chemicals for which toxicity information is lacking.
Burke, Thomas A, Fox, Mary A, Nachman, Keeve E, Rodricks, Joseph V, Sheehan, Mary C, Woodruff, Tracey J   +5 more
core  

Probabilities and health risks: a qualitative approach [PDF]

, 2002
Health risks, defined in terms of the probability that an individual will suffer a particular type of adverse health event within a given time period, can be understood as referencing either natural entities or complex patterns of belief which ...
Heyman, Bob
core   +1 more source

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Developmental and reproductive toxicity assessment of sporoderm-removed Ganoderma lucidum spores

Frontiers in Cell and Developmental Biology
IntroductionGanoderma lucidum is a fungus used in traditional Chinese medicine with high medicinal value and is also widely used in modern healthcare. Its spores are reported to contain antitumor and anti-inflammatory properties, among other biological ...
Junxiu Liu, Yisheng Song, Yisheng Song, Chuanhuai Chen, Jing Liu, Jing Liu, Siming Zhang, Fang Liu, Fang Liu, Ruiyu Tian, Jinjin Shao, Lili Zhang, Tingli Bian, Ruimin Sun, Li Yu, Shuizhen Pan, Yunxiang Chen, Yaoxian Xuan, Hanbo Wang, Zhenhao Li, Ying Chen, Lijiang Zhang, Lijiang Zhang   +22 more
doaj   +1 more source

Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs

ADMET and DMPK, 2013
The initial dose selection is one of the important steps for any investigative new drug (IND) entering the first clinical study in human. In this mini review, we will discuss the no observed adverse effect level (NOAEL) and the minimum anticipated ...
Kin Tam
doaj   +1 more source